EUCTR2020-001194-69-ES
Active, not recruiting
Phase 1
Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19
Félix Gutiérrez Rodero0 sites200 target enrollmentApril 7, 2020
ConditionsCOVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.Therapeutic area: Diseases [C] - Virus Diseases [C02]
DrugsLariam
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- COVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.
- Sponsor
- Félix Gutiérrez Rodero
- Enrollment
- 200
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •People in close contact with adults diagnosed with COVID\-19 who sign the informed consent. Close contact is defined as those who live at home with an infected person, who have had intimate relationships or whose job is less than two meters from the infected person.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 100
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 100
Exclusion Criteria
- •\-Patients \<18 years.
- •\-Patients with symptoms suggestive of SARS\-CoV\-2 infection.
- •\-Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.
- •\-Patients allergic to mefloquine or other quinine or quinidine\-type medications.
- •\-Patients with a neurological history (seizures, epilepsy, etc.).
- •\-Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).
- •\-Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non\-inclusion of the patient in the study.
- •\-Patients in treatment with other medications such as valproic acid, antiarrhythmics, antihistamines H1, beta\-blockers, calcium channel blockers, chloroquine, halofantrine, phenothiazines, quinidine and quinine.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Pilot study to evaluate the efficacy and safety of MegaNuovo in Pressure sore patients : single center, comparative, investigator-initiated pilot studyDiseases of the skin and subcutaneous tissueKCT0006745Yonsei University, Wonju Severance Christian Hospital30
Completed
Not Applicable
Safety and efficacy of Transcend CyPass glaucoma implant in open angle glaucoma patients who have failed medical treatmentPrimary open angle glaucomaEye DiseasesGlaucomaISRCTN23263504Transcend Medical, Inc.™ (USA)20
Completed
Not Applicable
Transcend CyPass glaucoma implant and cataract surgery in open angle glaucoma patientsISRCTN86839890Transcend Medical, Inc.™ (USA)20
Active, not recruiting
Not Applicable
A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemiaon Familial Chylomicronemia Syndrome (Non-FCS)MedDRA version: 14.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Non Familial Chylomicronemia Syndrome (Non-FCS)EUCTR2012-000872-40-CZovartis Pharma Services AG60
Completed
Phase 3
A pilot study to assess the efficacy and safety of Heliox inhalation therapy for resuscitation to preterm infants.preterm infantsJPRN-UMIN000015061agano Children's Hospital10